Screener
Veradermics MANE Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(27,232) | $(12,400) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 5,259 | 213 |
| Non-cash research and development services | 621 | 357 |
| Net accretion of discount/premium on debt securities | (73) | (13) |
| Other | 6 | 2 |
| Changes in operating assets and liabilities: |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's stock-based comp?
- Veradermics (MANE) reported stock-based comp of $5.26M in Q1 2026.
- How has Veradermics's stock-based comp changed year-over-year?
- Veradermics's stock-based comp increased by 2369.0% year-over-year, from $213K to $5.26M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Veradermics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude